Literature DB >> 2166753

Soluble Fc gamma receptor III in human plasma originates from release by neutrophils.

T W Huizinga1, M de Haas, M Kleijer, J H Nuijens, D Roos, A E von dem Borne.   

Abstract

FcRIII (the CD16-antigen), a low affinity receptor for IgG, is expressed by neutrophils, natural killer lymphocytes, and macrophages. We have developed a sensitive radioimmunoassay to quantify FcRIII. A soluble form of FcRIII was identified in human plasma. Immunoprecipitation of FcRIII from plasma showed that the plasma form of FcRIII has an identical electrophoretic mobility as the FcRIII expressed by neutrophils. Moreover, the plasma form of FcRIII exhibited the same polymorphism as does the neutrophil FcRIII. The neutrophil expresses the phosphatidylinositol-linked form of FcRIII, encoded by the gene FcRIII-1. Because it is not known whether this gene is also active in nonhematopoietic cells, we analyzed patients with an acquired clonal disorder of their hematopoietic cells, paroxysmal nocturnal hemoglobinuria (PNH). PNH patients appeared to have a strongly reduced expression of FcRIII on their neutrophils. The concentration of FcRIII in the plasma of these patients was also reduced, indicating that plasma FcRIII originates from neutrophils. A patient deficient in FcRIII-1 but with a normal expression of FcRIII-2 had no soluble FcRIII in her plasma, also indicating that plasma FcRIII originates from neutrophils. The electrophoretic mobility of the protein backbone of plasma FcRIII and FcRIII released by activated neutrophils was identical, whereas deglycosylated FcRIII obtained from a lysate of neutrophils migrated slower. This indicates that plasma FcRIII originates from activation-induced release by neutrophils. Stimulation of neutrophils or neutrophil cytoplasts (closed membrane vesicles filled with cytoplasm) with low concentrations of FMLP (10(-9)-10(-8) M) or phorbol myristate acetate (1-10 ng/ml) induced a dose-dependent release of FcRIII. The plasma concentration of FcRIII was relatively constant (range 40-280% of the mean). Soluble FcRIII was also detected in inflamed joint fluids of arthritis patients, suggesting that FcRIII is also released by activated neutrophils in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166753      PMCID: PMC296743          DOI: 10.1172/JCI114727

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms.

Authors:  B J Scallon; E Scigliano; V H Freedman; M C Miedel; Y C Pan; J C Unkeless; J P Kochan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

Review 2.  Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects.

Authors:  T W Kuypers; D Roos
Journal:  Res Immunol       Date:  1989 Jun-Aug

3.  The PI-linked receptor FcRIII is released on stimulation of neutrophils.

Authors:  T W Huizinga; C E van der Schoot; C Jost; R Klaassen; M Kleijer; A E von dem Borne; D Roos; P A Tetteroo
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

Review 4.  The human neutrophil. Function and dysfunction.

Authors:  N Borregaard
Journal:  Eur J Haematol       Date:  1988-11       Impact factor: 2.997

5.  Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils.

Authors:  P A Ory; M R Clark; E E Kwoh; S B Clarkson; I M Goldstein
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

6.  The 40-kDa Fc gamma receptor (FcRII) on human neutrophils is essential for the IgG-induced respiratory burst and IgG-induced phagocytosis.

Authors:  T W Huizinga; F van Kemenade; L Koenderman; K M Dolman; A E von dem Borne; P A Tetteroo; D Roos
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

7.  Characterization of polymorphic forms of Fc receptor III on human neutrophils.

Authors:  P A Ory; I M Goldstein; E E Kwoh; S B Clarkson
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

8.  Human Fc gamma RIII: cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG.

Authors:  G A Peltz; H O Grundy; R V Lebo; H Yssel; G S Barsh; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

9.  Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes.

Authors:  L L Lanier; J H Phillips; R Testi
Journal:  Eur J Immunol       Date:  1989-04       Impact factor: 5.532

10.  Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.

Authors:  J V Ravetch; B Perussia
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more
  42 in total

1.  The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

Authors:  P E Dekkers; T ten Hove; F N Lauw; H R Koene; P Lumley; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions.

Authors:  David F Stroncek; Emmanuel Fadeyi; Sharon Adams
Journal:  Transfus Med Rev       Date:  2007-10

3.  Isolation and purification of an early pregnancy factor-like molecule from culture supernatants obtained from lymphocytes of pregnant women: II. Identification of the molecule as a Fc-receptor-like molecule: a preliminary report.

Authors:  C Aranha; A Bordekar; S Shahani
Journal:  J Assist Reprod Genet       Date:  1998-11       Impact factor: 3.412

4.  Levels of soluble Fc gammaRIII correlate with disease severity in sepsis.

Authors:  A C Muller Kobold; J G Zijlstra; H R Koene; M de Haas; C G Kallenberg; J W Tervaert
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

5.  Altered expression of Fc gammaRIII (CD16) on polymorphonuclear neutrophils from individuals with human immunodeficiency virus type 1 disease and pulmonary tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

6.  Granulocyte chemiluminescence response to serum opsonized zymosan particles ex vivo during long-term strenuous exercise, energy and sleep deprivation in humans.

Authors:  P Wiik; P K Opstad; A Bøyum
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

7.  Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils.

Authors:  L A Sanders; R G Feldman; M M Voorhorst-Ogink; M de Haas; G T Rijkers; P J Capel; B J Zegers; J G van de Winkel
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils.

Authors:  Yue Wang; Jianming Wu; Robert Newton; Nooshin S Bahaie; Chunmei Long; Bruce Walcheck
Journal:  Biochim Biophys Acta       Date:  2012-12-08

9.  Iso-immune neonatal neutropenia due to an anti-Fc receptor III (CD16) antibody.

Authors:  J Cartron; J L Celton; P Gane; A Astier; W H Fridman; G Boissinot; J P Cartron
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

10.  Surface expression of Fc gamma receptor III (CD16) on chemoattractant-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments.

Authors:  M F Tosi; H Zakem
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.